Testosterone replacement therapy improves sexual desire, erectile function in men with T2DM

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In men with type 2 diabetes mellitus (T2DM), testosterone replacement treatment (TRT) significantly improves sexual desire (SxD) in a greater proportion of men than placebo after 6 wk while the corresponding improvement in erectile function (EF) occurs later at 30 wk.

Why this matters

  • SxD change after 6 wk predicting EF change at 30 wk is possibly a useful clinical finding.

Study design

  • Using baseline total testosterone (TT)/free testosterone (FT), 30-wk randomised controlled study stratified 199 participants with T2DM into Mild (TT 8.1–12 nmol/L or FT 0.18–0.25 nmol/L) and Severe HG groups (TT ≤8 nmol/L and FT ≤0.18 nmol/L) and placebo – and testosterone undecanoate (TU)-treated groups.
  • Associations between TU, SxD, and EF were investigated.
  • Funding: None disclosed.

Key results

  • Compared with placebo, a higher proportion of men in the severe HG group demonstrated improved SxD after 6 wk following TU treatment (Severe HG/P: 21.2%, Severe HG/TU: 60.0%, P<.001).
  • Similarly, the proportion of men with improved EF after 30 wk was significantly higher in severe HG men.
  • Logistic regression showed that SxD score at 6 wk (OR 3.31; P=.001) was significantly associated with the 30-wk EF score.

Limitations

  • Small sample size.